Tag: Stents
No Increased Mortality Seen With Paclitaxel Drug-Eluting Devices
In safety analysis, long-term mortality did not increase with use of paclitaxel-based devices
PCI, CABG for Left Main CAD Have Similar Five-Year Outcomes
Findings reported for composite outcomes for 1,905 patients with left main coronary artery disease
In STEMI, Biodegradable Polymer Sirolimus-Eluting Stents Superior
Stents superior to durable polymer everolimus-eluting stents for end point of target lesion failure at one year
PCI Beneficial for All Categories of Older AMI Patients
PCI linked to improved survival versus medical therapy for young-old, middle-old, and old-old patients
FDA Issues Update on Mortality Risk With Paclitaxel-Coated Products
Preliminary analyses revealed approximately 50 percent increased risk at five-year follow-up
FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents
Investigation triggered by meta-analysis showing possible increased mortality in PAD patients at 2 years
Volumes Low for Unprotected Left Main PCI
Real-world procedures performed on older, comorbid patients, lead to more adverse events
Second-Gen Drug-Eluting Stents Similarly Effective for LMCAD
Only one significant between-group difference in three-year risk of target-vessel failure for left main CAD
Odds for Carotid Artery Stenting in Seniors Up Post-CREST Era
Increase in odds of receiving CAS in all patients older than 70 years and in symptomatic women
Thrombosis Odds Up With Bioresorbable Vascular Scaffolds
BVSs linked to increased risk of MI, target lesion revascularization and failure versus metallic stents
